PARP Inhibitors: Recent Research Advancements in Prostate Cancer (2025–2026)
PARP inhibitors are among the most significant advances in precision medicine for prostate cancer. These drugs work by blocking DNA […]
Two New Approvals, One Clear Direction — Targeted Drug Therapies Come of Age in 2025
The past year brought two significant FDA approvals that signal where prostate cancer treatment is heading: toward more precise, earlier-acting […]
“Smart” Radiation Gets Smarter — Lutetium-177 Therapy Expands Its Reach
A treatment once reserved for men who had exhausted nearly every other option is now available earlier in the course […]
A New Standard in Detection — PSMA PET Imaging Is Changing How We Find Prostate Cancer
For decades, diagnosing and staging prostate cancer relied on a combination of CT scans, bone scans, and MRI. That picture […]
June 2026
Includes: Study finds prostate cancer overdiagnosis rises sharply with age, experimental drug shows promise for patients with advanced prostate cancer,
May 2026
Includes: exposing a new weakness in prostate tumors, delaying disease progression, prostate cancer overdiagnosis rises sharply with age,
Tribute Giving
Some people leave a lasting mark on our lives. A tribute gift is a simple, meaningful way to honour someone […]
April 2026
Includes: Researchers praise results of new prostate cancer treatment, glowing cancer cells could cut need for biopsies, Prostate cancer deaths to decrease,
Partner With Prostaid Calgary
Prostaid Calgary is the oldest and primary prostate cancer support group in Calgary, having been formed in 1933 Celebrating over […]
March 2026
Includes: New characteristics of aggressive prostate cancer identified, how to treat recurring prostate cancer, apalutamide vs. darolutamide in mCSPC,